Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nafabelltan (Chong Kun Dang Holdings)
- Development stage
- Phase 2
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Nafabelltan (CKD-314) is a synthetic small molecule serine protease inhibitor developed by Chong Kun Dang. It is closely related to nafamostat and has been investigated primarily for the treatment of COVID-19 pneumonia. Nafabelltan acts by inhibiting a range of serine proteases involved in coagulation and inflammation, including thrombin, plasmin, kallikrein, trypsin, complement system proteases (Cl esterase), and coagulation factors VIIa, Xa, and XIIa. It also inhibits transmembrane protease serine 2 (TMPRSS2), which plays a key role in viral entry for coronaviruses such as SARS-CoV-2. This mechanism underlies its potential antiviral activity against COVID-19[5][7][9]. Nafabelltan has anticoagulant and anti-inflammatory properties as well.
- Brand names
- Nafabelltan
- Other names
- nafamostatFUT-175FUT175FUT 175
02
Targets
TMPRSS2 (Transmembrane protease serine 2)PLG (Plasminogen)F2 (Thrombin)
Beyond the preview
Go deeper on nafabelltan (Chong Kun Dang Holdings).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nafabelltan (Chong Kun Dang Holdings).